Lonsurf FDA Approval History
FDA Approved: Yes (First approved September 22, 2015)
Brand name: Lonsurf
Generic name: tipiracil hydrochloride and trifluridine
Dosage form: Capsules
Company: Taiho Oncology, Inc.
Treatment for: Colorectal Cancer, Gastric Cancer
Lonsurf (tipiracil and trifluridine) is a thymidine phosphorylase inhibitor and nucleoside metabolic inhibitor combination indicated for the treatment of patients with previously treated metastatic colorectal cancer, and previously treated metastatic gastric or gastroesophageal junction adenocarcinoma.
Development Timeline for Lonsurf
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.